Diagnostic and Prognostic Value of Serum Procalcitonin in Pneumonia - A Prospective Observational Study
Abstract
Objectives: Community-acquired and nosocomial respiratory tract infections are public health problems of major concern and a leading cause of mortality. In the current prospective observational study, we intend to study the utility of procalcitonin (PCT) estimation in the diagnosis and prognosis of Community-acquired Pneumonia (CAP) and Ventilator-associated Pneumonia (VAP).
Materials and Methods: The study was conducted over a period of two years. 40 patients with diagnosis of CAP and 40 patients of VAP were included in the study. Serum Procalcitonin levels were estimated using BRAHMS PCT Kryptor Immunofluorescent Assay (Biomerieux, France). Other routine investigations including sputum culture and endotracheal secretions cultures were done. Chi-square analysis was done to assess its prognostic and diagnostic significance.
Results: PCT was positive (> 0.05ng/ml) in 68% patients with CAP and 80% patients with VAP. Higher absolute values of PCT were seen in patients with VAP compared to CAP. In VAP PCT was positive in more patients with bronchopneumonia than lobar pneumonia. Streptococcus pneumoniae was the most common bacterial etiology of CAP, and was associated with a positive PCT in 75% cases. Acinetobacter was the most common bacterial etiology of VAP, and was associated with a positive PCT in 80% cases. Mortality was more in PCT positive patients in both CAP and VAP. Maximum mortality in VAP was with PCT >10 ng/ml.
Conclusion: PCT is a useful adjuvant in the diagnosis of both CAP and VAP. Positive PCT levels indicate a bacterial etiology for pneumonia. A high PCT level is a poor prognostic indicator and is associated with a higher mortality.
Keywords
Full Text:
PDFReferences
Black AD. Non-infectious mimics of communityacquired
pneumonia. Pneumonia 2016; 8(2): 1-5.
Becker KL, Snider R, Nylen ES. Procalcitonin in sepsis
and systemic inflammation: a harmful biomarker and
a therapeutic target. British Journal of Pharmacology
; 159(2): 253-264.
Niederman MS, Mandell LA, Anzueto A et al. Guidelines
for the management of adults with communityacquired
pneumonia. Am J Respir Crit Care Med 2001;
(7): 1730-54.
Chastre J, Fagon JY. Ventilator-associated pneumonia.
Am J Respir Crit Care Med 2002; 165(7): 867-903.
Huang DT, Lisa A, Weissfeld et al. Risk prediction with
procalcitonin and clinical rules in community-acquired
pneumonia. Ann Emerg Med 2008; 52(1): 48-58.
Masiá M, Gutiérrez F, Shum C et al. Usefulness of
procalcitonin levels in community-acquired pneumonia
according to the patient’s outcome research team
pneumonia severity index. Chest 2005; 128(4): 2223-9.
Holm A, Pedersen SS, Nexoe J et al. Procalcitonin versus
C-reactive protein for predicting pneumonia in adults
with lower respiratory tract infection in primary care.
Br J Gen Pract 2007; 57(540): 555-60.
Müller B, Harbarth S, Stolz D et al.Diagnostic and
prognostic accuracy of clinical and laboratory
parameters in community-acquired pneumonia. BMC
Infect Dis 2007; 2(7): 10.
Boussekey N, Leroy O, Georges H et al. Diagnostic and
prognostic values of admission procalcitonin levels in
community-acquired pneumonia in an intensive care
unit. Infection 2005; 33(4): 257-63.
Hedlund J, Hansson LO. Procalcitonin and C-reactive
protein levels in community-acquired pneumonia:
correlation with aetiology and prognosis. Infection
; 28(2): 68-73.
Lee JY, Hwang SJ, Shim JW et al. Clinical Significance
of Serum Procalcitonin in Patients with Communityacquired
Lobar Pneumonia. Korean J Lab Med 2010;
(4): 406-13.
Krüger S, Ewig S, Marre R et al. Procalcitonin predicts
patients at low risk of death from community-acquired
pneumonia across all CRB-65 classes. Eur Respir J 2008;
: 349-355.
Daubin C, Parienti JJ, Fradin S et al. Procalcitonin levels
and bacterial aetiology among COPD patients admitted
to the ICU with severe pneumonia: a prospective cohort
study. BMC Infect Dis 2009; 9: 157.
Jereb M, Kotar T. Usefulness of procalcitonin to
differentiate typical from atypical community-acquired
pneumonia. Wien Klin Wochenschr 2006; 118(5-6):
-4.
Nyamande K, Lalloo UG. Serum procalcitonin
distinguishes CAP due to bacteria, Mycobacterium
tuberculosis and PJP. Int J Tuberc Lung Dis 2006; 10(5):510-5.
Boussekey N, Leroy O, Alfandari S et al. Procalcitonin
kinetics in the prognosis of severe community-acquired
pneumonia. Intensive Care Med 2006; 32(3): 469-72.
Ramirez P, Garcia MA, Ferrer M et al. Sequential
measurements of procalcitonin levels in diagnosing
ventilator-associated pneumonia. Eur Respir J 2008;
: 356-62.
Duflo F, Debon R, Monneret G et al. Alveolar and
serum procalcitonin: diagnostic and prognostic value
in ventilator-associated pneumonia. Anaesthesiology
; 96(1): 74-9.
Luyt CE, Guerin V, Combes A et al. Procalcitonin
kinetics as a prognostic marker of ventilator-associated
pneumonia. Am J Respir Crit Care Med 2005; 171:
-53.
Seligman R, Meisner M, Lisboa T et al. Decreases
in procalcitonin and C-reactive protein are strong
predictors of survival in ventilator-associated
pneumonia. Crit Care 2006; 10: R125.
Brunkhorst FM, Al-Nawas B, Krummenauer F et al.
Procalcitonin, C-reactive protein and APACHE II score
for risk evaluation in patients with severe pneumonia.
Clin Microbiol Infect 2002; 8(2): 93-100.
Polzin A, Pletz M, Erbes R et al. Procalcitonin as a
diagnostic tool in lower respiratory tract infections and
tuberculosis. Eur Respir J 2003; 21: 939-43.
Refbacks
- There are currently no refbacks.
Copyright (c) 2018 Journal of Advanced Research in Medicine (P-ISSN:2394-7047 & E-ISSN:2349-7181)

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.